--- title: "Intensity Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285659468.md" datetime: "2026-05-08T03:41:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285659468.md) - [en](https://longbridge.com/en/news/285659468.md) - [zh-HK](https://longbridge.com/zh-HK/news/285659468.md) --- # Intensity Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.96, beating the estimate of USD -1.1067. EBIT: As of FY2026 Q1, the actual value is USD -2.62 M. #### Net Loss and Accumulated Deficit Intensity Therapeutics, Inc. reported a net loss of - $2.4 million for the three months ended March 31, 2026, which is a decrease of $913 thousand compared to a net loss of - $3.3 million for the same period in 2025. The company’s accumulated deficit was - $80.8 million as of March 31, 2026. #### Operating Expenses Total operating expenses were - $2,526 thousand for the three months ended March 31, 2026, a decrease from - $3,394 thousand for the same period in 2025. - **Research and Development (R&D) Expenses**: R&D expenses decreased by - $994 thousand, or 45%, to - $1,195 thousand for the three months ended March 31, 2026, from - $2,189 thousand in the prior year period. - INVINCIBLE-3 Study (Phase 3 Sarcoma) costs decreased by - $1,103 thousand to - $493 thousand for Q1 2026, primarily due to pausing new site activations and patient enrollments. - INVINCIBLE-4 Study (Phase 2 Breast) costs increased by - $55 thousand to - $118 thousand for Q1 2026. - Contract manufacturing costs increased by - $9 thousand to - $33 thousand for Q1 2026. - Salaries and benefits related to R&D remained constant at - $329 thousand for both periods. - Consulting & Other R&D expenses increased by - $54 thousand to - $71 thousand for Q1 2026. - Stock-based compensation for R&D decreased by - $11 thousand to - $149 thousand for Q1 2026. - **General and Administrative (G&A) Expenses**: G&A expenses marginally increased by - $126 thousand, or 10%, to - $1,331 thousand for the three months ended March 31, 2026, from - $1,205 thousand in the prior year period. - Salaries and benefits related to G&A increased by - $51 thousand to - $281 thousand for Q1 2026, partly due to an estimated bonus accrual. - Legal fees decreased by - $6 thousand to - $161 thousand for Q1 2026. - Audit fees increased by - $11 thousand to - $88 thousand for Q1 2026. - Consulting G&A expenses decreased by - $1 thousand to - $195 thousand for Q1 2026. - Insurance costs increased by - $12 thousand to - $169 thousand for Q1 2026. - Other G&A expenses increased by - $95 thousand to - $198 thousand for Q1 2026, partly due to one-time expenses related to the Reverse Stock Split. - Stock-based compensation for G&A decreased by - $36 thousand to - $239 thousand for Q1 2026. #### Other Income/Expense Interest income was $94 thousand for the three months ended March 31, 2026, an increase from $15 thousand for the same period in 2025. Other (expense) income, net, was - $2 thousand for Q1 2026, compared to $32 thousand for Q1 2025. #### Cash Flow - **Net cash used in operating activities** was - $1,826 thousand for the three months ended March 31, 2026, compared to - $1,989 thousand for the same period in 2025. - **Net cash provided by financing activities** was $150 thousand for the three months ended March 31, 2026, compared to $328 thousand for the same period in 2025, entirely from net proceeds received from At The Market (ATM) offerings. - **Net decrease in cash and cash equivalents** was - $1,676 thousand for the three months ended March 31, 2026, compared to - $1,661 thousand for the same period in 2025. #### Liquidity and Capital Resources As of March 31, 2026, cash and cash equivalents totaled $10.2 million. The company plans to finance operations through equity offerings and convertible debt financings, with the ability to sell up to $60.0 million of common stock under its ATM Sales Agreement as of March 23, 2026. Subsequent to March 31, 2026, an additional $0.6 million was raised from the issuance of 124,553 shares under the Sales Agreement. #### Future Outlook and Strategy Intensity Therapeutics, Inc. expects significant expenses and operating losses for several years due to funding clinical studies, manufacturing costs, regulatory approvals, and establishing commercialization infrastructure. The INVINCIBLE-3 Study (Phase 3 Sarcoma) enrollment, paused due to funding, is planned to resume in limited U.S. sites by Q3 2026 upon securing sufficient incremental funding. The INVINCIBLE-4 Study (Phase 2 Breast) enrollment, which was paused to revise dosing, received full approval to resume on March 26, 2026, and is expected to restart in Q2 2026, targeting completion by the end of 2027. ### Related Stocks - [INTS.US](https://longbridge.com/en/quote/INTS.US.md) ## Related News & Research - [Spero Therapeutics CMO Debra Zack files initial beneficial ownership statement](https://longbridge.com/en/news/295153314.md) - [Palvella Therapeutics CEO joins Canaccord Genuity Growth Conference fireside chat](https://longbridge.com/en/news/294958978.md) - [REG - Thalia Therapeutics - Holding(s) in Company](https://longbridge.com/en/news/294798238.md) - [Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call](https://longbridge.com/en/news/294837772.md) - [Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday](https://longbridge.com/en/news/294710967.md)